-
Mashup Score: 37
PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, o
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hematologists1, Latest HeadlinesTweet-
Ending the week with good news: initial analysis of the GAZELLE study, which I had the opportunity to coordinate, has just been published @Hemasphere_EHA Obinutuzumab Can Be Administered as a 90-minute SDI. Huge thanks to the patients and their families https://t.co/o53qY3CYnY
-
-
Mashup Score: 1abbrevia.me - 1 year(s) ago
abbreviate users’ information from their latest tweets.
Source: abbrevia.meCategories: Hem/Oncs, Latest HeadlinesTweet-
Vía https://t.co/kni3yd9ouo 👇 #AI #SoMe https://t.co/Oa7PcNDN0i
-
I have just discovered https://t.co/kni3yd9ouo, do you think it is right?👇 https://t.co/GHHnI8NAOb https://t.co/loGwj3C4Qo
-
-
Mashup Score: 1Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma - 1 year(s) ago
Key Points. Bridging therapy (BT) is safe, and complete/partial response to BT confers a 42% reduction in risk of progression/death post-CD19CAR-TGood response
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
A must-read paper via @BloodAdvances Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma https://t.co/dEPeRaTpM4 https://t.co/7MfG9Ow3AQ
-
-
Mashup Score: 3
La Unidad Docente de Hematología de la Clínica Universidad de Navarra ofrece a los residentes la posibilidad de una formación de calidad en todas las áreas q…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @paurotero: Te esperamos!! … Haz tu residencia MIR en Hematología en la Clínica Universidad de Navarra https://t.co/RRFjNSHRvG vía @YouT…
-
-
Mashup Score: 0
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study | Journal of Clinical Oncology https://t.co/xt1CQrnaGP
-
-
Mashup Score: 8LA CUADRI DEL HOSPI & FITO "Acabo de Llegar" - 2 year(s) ago
Este vídeo forma parte de un proyecto benéfico de recaudación de fondos para la investigación del cancer infantil organizado por la asociación de padres y ma…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Ayuda a difundirlo!!! Lo han grabado en @OSIEECruces Fito y los Fitipaldis con niños con cáncer y enfermeras … cuántas más veces se envíe, más dinero se recaudará para la #investigación sobre el #cáncer 🙏🙏🙏 https://t.co/14YzZHbNnq https://t.co/14YzZHbNnq
-
-
Mashup Score: 5
El Dr. Miguel Canales, Jefe del Servicio de Hematología del Hospital Universitario La Paz de Madrid, nos comentó respecto del uso de anticuerpos bi-específic…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @LymphomaEx: @DrMCanales acerca del uso de anticuerpos bi-específicos en #LEx2022 https://t.co/FupBugBWGd https://t.co/eQ9bAf0Wai
-
-
Mashup Score: 1
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hematologists1, Latest HeadlinesTweet-
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study #lymsm #bmtsm https://t.co/0V8bqy5NGF
-
-
Mashup Score: 0Mantle-Cell Lymphoma | NEJM - 2 year(s) ago
Review Article from The New England Journal of Medicine — Mantle-Cell Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Vacation work time 🤓 📖 Review on Mantle-Cell Lymphoma via @NEJM https://t.co/rEwXErv4sQ
-
Just published @JCO_ASCO. Kudos to @gloria_iacoboni 👏👏👏👇 Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy https://t.co/hSgv6eg9gb